Movement Alert｜Gilead Sciences After-Hours Rise 3.25%, Q3 Revenue and Adjusted EPS Beat Expectations

Market Focus05:08

On October 30, Gilead Sciences rose 3.25% in After-Hours Trading, trading at $169.2/share, with turnover of $58.524 million.

The move followed the company’s quarterly results, which came in ahead of market expectations. Gilead reported Q3 adjusted earnings of $2.55 per diluted share versus $2.19 expected, while revenue rose to $8.30 billion from $7.77 billion a year earlier and topped the $7.81 billion consensus.

The earnings beat reinforced investor focus on the company’s core HIV franchise and oncology products including Trodelvy. At the same time, Gilead updated full-year guidance, raising its product sales outlook to $31.00 billion-$31.30 billion from $30.10 billion-$30.40 billion, while projecting a wider adjusted loss range of $1.20-$0.85 per share.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment